Docoh
Loading...

PFE Pfizer

APP
Utility
Orally Administered Combinations of Beta-lactam Antibiotics and Avibactam Derivatives for Treating Bacterial Infections
4 Mar 21
Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed.
JOAQUIM TRIAS, CAROLE SABLE, ANDREW NICHOLLS
Filed: 27 Aug 20
APP
Utility
Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore
4 Mar 21
Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
Filed: 6 Nov 20
APP
Utility
ANTI-IL-2 Antibodies and Compositions and Uses Thereof
4 Mar 21
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.
Isaac J. RONDON, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
Filed: 9 Jul 20
GRANT
Utility
GLP-1 receptor agonists and uses thereof
2 Mar 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 10 Jun 19
APP
Utility
Therapeutic Antibodies and Their Uses
25 Feb 21
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3).
Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
Filed: 27 Aug 20
GRANT
Utility
Anti-CXCR4 antibodies and antibody-drug conjugates
23 Feb 21
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4).
Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
Filed: 8 Aug 19
APP
Utility
GLP-1 Receptor Agonists and Uses Thereof
18 Feb 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 30 Oct 20
APP
Utility
N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
18 Feb 21
Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
Filed: 28 Sep 20
GRANT
Utility
Unknown
16 Feb 21
The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation.
Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
Filed: 17 Sep 18
APP
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
11 Feb 21
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 28 May 20
APP
Utility
Humanized Antibodies
11 Feb 21
Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody.
William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
Filed: 1 Apr 20
APP
Utility
LFA3 Variants and Compositions and Uses Thereof
4 Feb 21
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules.
Natasha Kay CRELLIN, Lauren Kate ELY, Jason Robles REYES, Chia Chi HO, Jeffrey A. BLUESTONE, Eleonora TROTTA, Qizhi TANG
Filed: 28 Sep 20
GRANT
Utility
Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
2 Feb 21
Agustin Casimiro-Garcia, Joseph Walter Strohbach, David Hepworth, Frank Eldridge Lovering, Chulho Choi, Christophe Philippe Allais, Stephen Wayne Wright
Filed: 7 Jul 17
GRANT
Utility
Recombinant ROBO2 proteins, compositions, methods and uses thereof
2 Feb 21
The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors.
Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
Filed: 1 Jun 18
APP
Utility
Methods of Administering Chimeric Antigen Receptor Immunotherapy In Combination with 4-1BB Agonist
28 Jan 21
The disclosure provides a method of treatment of a B-cell lymphoma or leukemia, including diffuse large B-cell lymphoma (DLBCL) comprising a CD19-directed chimeric antigen receptor (CAR) genetically modified T-cell immunotherapy in combination with a 4-IBB (CD137) agonist.
William Y. GO, Adrian WOOLFSON
Filed: 15 Jan 19
APP
Utility
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
28 Jan 21
The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation.
Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
Filed: 1 Oct 20
APP
Utility
RSV F Protein Mutants
28 Jan 21
The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
Filed: 1 Oct 20
APP
Utility
Piperazine Azaspiro Derivaves
28 Jan 21
Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney, Laura Ann McAllister, Qingyi Yang, Christopher John Helal, Damien Webb
Filed: 25 Mar 19
APP
Utility
BCKDK Inhibitors
28 Jan 21
Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
Filed: 26 Jun 20
APP
Utility
Neisseria Meningitidis Composition and Methods Thereof
28 Jan 21
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof.
Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen
Filed: 30 Sep 20
Patents are sorted by USPTO publication date, most recent first